 OUTLINE: This is a multicenter study. Patients are stratified by center, type of systemic therapy trastuzumab Herceptin monotherapy vs combination with chemotherapy, hormone receptor status, and presence of lung metastases yes vs no. Patients are randomized to 1 of 2 treatment arms. 